A First-in-human Safety, Tolerability and Pharmacokinetics study of Benapenem in Healthy Chinese Volunteers.
Cai-Yun Zhao,Yuan Lv,Yan Zhu,Min-Ji Wei,Meng-Ying Liu,Xi-Wei Ji,Zi-Sheng Kang,Ya-Hong Xia,Ji-Hong Tian,Yan Ma,Yan Liu
DOI: https://doi.org/10.1128/AAC.02188-18
IF: 5.938
2019-01-01
Antimicrobial Agents and Chemotherapy
Abstract:The objective of this trial was to investigate the safety, tolerability, and pharmacokinetics (PK) of benapenem administered by single or multiple intravenous infusions in healthy Chinese volunteers. The trial was divided into 3 parts. In part A, 94 subjects were enrolled in a double-blind, placebo-controlled, sequential-ascending-single-dose study. The subjects were randomly assigned to groups receiving placebo or benapenem for injection at doses of 62.5, 125, 250, 500, 1,000, 2,000, or 3,000 mg. The effects of intravenous infusion time on the subjects of 250- ,500-, and 1,000-mg groups were explored. In part B, 12 subjects were enrolled in a single-dose PK study under fasting conditions and received 250, 500, or 1,000 mg of benapenem for injection. In part C, 36 subjects were given 250, 500, and 1,000 mg of benapenem for injection once daily for 7 consecutive days. The results showed that benapenem for injection was well tolerated during the studies. The major observed adverse events were mild, and all were resolved spontaneously without any medical intervention. Benapenem was mainly excreted through the kidneys in the form of parent molecule and metabolites. The PK and safety profiles of benapenem in healthy Chinese volunteers support its once-daily dosing in future clinical investigations.